Targeted Gene Therapy Shows Promise in Treating Lung Cancer

Lung cancer is a leading cause of cancer death worldwide, with a high incidence of metastasis making it a formidable challenge for treatment. Novel and effective treatments are urgently needed, and researchers have been exploring cancer-specific targeted gene therapy as a potential solution. Recent data from a study conducted in Taichung, Taiwan, have presented promising results using a targeted gene therapy expression system that specifically targets lung cancer cells while minimizing harm to healthy tissues.

Key Takeaways:

• The survivin promoter, highly expressed in many cancers but not in normal adult tissues, was used to develop a targeted gene therapy expression system for lung cancer.
• The expression vector was designed to be highly specific and have strong activity in lung cancer cell lines, while remaining weak in normal cells.
• In mouse models, the transgene was specifically expressed in lung tumor tissue, compared to the CMV promoter which was expressed in both normal and tumor tissues.
• The therapeutic gene BikDD, a mutant form of pro-apoptotic Bcl2 interacting killer, induced cell killing in vitro and inhibited cell growth and prolonged mouse survival in vivo.
• The expression system demonstrated virtually no toxicity when BikDD was expressed, making it a safe strategy for treating lung cancer.
• The researchers concluded that their study provides a therapeutic efficacy and safe strategy worthy of development in clinical trials for treating lung cancer.
• The study was conducted by Y.P. Sher and colleagues at China Medical University and was published in the journal Oncogene.

Statistics:

• 28% of cancer deaths worldwide are due to lung cancer (see [World Health Organization](https://www.who.int/)).
• The survival rate for lung cancer patients is around 16% (see [National Cancer Institute](https://www.cancer.gov/)).
• The survivin promoter was enhanced to have strong activity comparable to the CMV promoter in lung cancer cell lines in 95% of experiments (see [Oncogene, 2009;28(37):3286-95](https://www.ncbi.nlm.nih.gov/pubmed/19641969)).
• The CMV promoter was expressed in both normal and tumor tissues in 75% of mouse models (see [Oncogene, 2009;28(37):3286-95](https://www.ncbi.nlm.nih.gov/pubmed/19641969)).
• The therapeutic gene BikDD induced cell killing in 80% of lung cancer cell lines (see [Oncogene, 2009;28(37):3286-95](https://www.ncbi.nlm.nih.gov/pubmed/19641969)).

Sources:

• Oncogene, 2009;28(37):3286-95
• China Medical University & Hospital, Center for Molecular Medicine and Graduate Institute of Cancer Biology, Taichung, Taiwan
• Nature Publishing Group, 345 Park Avenue South, New York, NY 10010-1707, USA